| University Utrecht |
The IRAS institute, University Utrecht. IRAS (Prof W.Seinen) already has a longstanding cooperation with Alloksys and houses both office and laboratory space that Alloksys uses. Thus also the central university animal facility is made accessible to Alloksys
Alloksys has established national and international partners with both academic and biotech companies under joint EU-framework 6 program
Partnerships are being set-up both in the USA for clinical and development activities.
CEVEC Pharmaceuticals, IBET
The development of a human recombinant alkaline phosphatase, to be applied for chronic inflammatory diseases, is planned in cooperation with CEVEC Pharmaceuticals (Koln, Germany, http://www.cevec-pharmaceuticals.com) and IBET (Oeiras, Portugal, http://www.ibet.pt).
BIDMC/Harvard, , Maidstone and Catharina Hospital Eindhoven (CZE)
A follow-up phase IIIa clinical trial in complicated cardiovascular (APPIRED II) in cooperation with CZE (Catharina Hospital Eindhoven, The Netherlands). A phase II clinical trial in variceal bleeding and organ transplant is planned in cooperation with Beth Israel Deaconess Hospital, Harvard, Boston,USA). At Maidstone (UK) a RA trial will be conducted.
AIX Scientifics. Principal CRO company based in Aachen, Germany (www. aix-scientifics.com). |
 |
| 
Press releases
|
24 nov 2011: Hoopgevend onderzoek aan veelzijdig nieuw type geneesmiddel |
| Onderzoeksresultaten ondersteunen de theorie dat diverse aandoeningen
kunnen worden bestreden of voorkomen door toediening van bepaalde, van nature in het lichaam voorkomende, enzymen. Deze aandoeningen betreffen met name ontstekingsreacties en deze onde... |
| Read more.. |
|
Alloksys Life Sciences announces positive results with alkaline phosphatase in a phase IIa Clinical Trial in Patients undergoing CABG surgery with CPB. |
| Bunnik, The Netherlands, 23 April 2008 - Dutch biotechnology company Alloksys Life Sciences announces the successful completion of a phase IIa clinical trial (APPIRED) in patients undergoing bypass surgery with cardiopulmonary bypass... |
| Read more.. |
|
Drug development program started based on CAP Human Cell Line. New platform may provide solutions for many RA-patients around the world. |
| Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce the start of Theraptech, a 2.4 million Euro therapeutic protein development program.... |
| Read more.. |
|
IBET joins ETB Theraptech project |
| IBET (Oeiras, Portugal) joins the Theraptech project. Theraptech aims to develop rec human ALP to be applied in arthritides diseases (e.g. RA and ankylosing spondylitis) as a preferred alternative to current TNFa blockers with a different MOA... |
| Read more.. |
|
New Experimental Medicine in EHEC |
| Bunnik, The Netherlands, June 7, 2011.
Dutch biopharmaceutical company Alloksys Life Sciences has an experimental medicine
which might help to counteract the effects of an EHEC infection.
"We now have over 10 years scientific research ....... |
| Read more.. |
|
Nieuw Experimenteel Medicijn in EHEC |
| Bunnik, 7 juni 2011.
Het Nederlandse biotechnologiebedrijf Alloksys Life Sciences heeft een experimenteel medicijn wat mogelijk kan helpen de gevolgen tegen te gaan van een EHEC-besmetting.
"We hebben inmiddels meer dan 10 jaar wetenschappelijk ....... |
| Read more.. |
|